<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) have an increased risk of developing <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Risk factors are extent and severity of colonic <z:mp ids='MP_0001845'>inflammation</z:mp>, concurrent primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp>, and a positive family history of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:mp ids='MP_0008866'>chromosomal instability</z:mp>, microsatellite instability and hypermethylation pathways form the molecular background of IBD-related <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, which is not different from <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> sequence of IBD-related colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> makes patients suitable for endoscopic surveillance </plain></SENT>
<SENT sid="4" pm="."><plain>In the future, new molecular biomarkers and endoscopic techniques may improve early detection of precursor lesions of IBD-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The potential of aminosalicylates and <z:chebi fb="1" ids="9907">ursodeoxycholic acid</z:chebi> as chemopreventive agents needs to be studied in randomized clinical trials </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with IBD who are being treated with <z:chebi fb="0" ids="35666">thiopurines</z:chebi> have a slightly increased risk of developing <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>, whereas patients with small bowel <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> have a high relative risk and a small absolute risk of developing small bowel <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>